Mr.Initiate

MR.INITIATE is a project from the Universitat Autònoma de Barcelona UAB (Bellaterra)

Mr.Initiate

MR.INITIATE is a project from the Universitat Autònoma de Barcelona UAB (Bellaterra)
Institution: UAB
Research group: Biomedical Applications of Magnetic Resonance research group (GABRMN)
Principal investigator: Carles Arús

The Problem

High grade gliomas (HGG), including glioblastoma, are the most common malignant primary brain tumour types. Advances in treating HGG are hampered by the lack of good non-invasive biomarkers for early response or relapse. Magnetic Resonance techniques are unique and indispensable for non-invasive metabolic imaging, and could make a difference in oncology and neurology. Despite its huge proven potential, MRS(I) is not yet a routine clinical tool operated solely by clinicians, as this requires reliable automation of complex procedures, strengthening standardization and quality control.
MR.INITIATE is a software product that rapidly indicates whether a therapeutic protocol for glioblastoma is being effective or not, before changes in tumour volumes are detected. With a machine learning approach, the product is able to process and postprocess nuclear magnetic resonance data (MRSI/MRI/MRS) to evaluate non-invasively the therapy response level within the tumour, in preclinical and clinical glioblastoma.

The Solution

The Solution

MR.INITIATE is a software product that rapidly indicates whether a therapeutic protocol for glioblastoma is being effective or not, before changes in tumour volumes are detected. With a machine learning approach, the product is able to process and postprocess nuclear magnetic resonance data (MRSI/MRI/MRS) to evaluate non-invasively the therapy response level within the tumour, in preclinical and clinical glioblastoma.

Purpose

MR.INITIATE has the potential to evaluate the effectiveness of conventional therapeutic agents earlier (personalized approach), as well as to evaluate novel therapeutic strategies in preclinical glioblastoma.
Time to market: 2 years
Looking for: Clinical and preclinical scanner vendors, as well as researchers, clinicians or pharmaceutical companies interested in the software.
Technology: Big Data & Analytics
Area: Disease Management & Therapeutics
TRL: 3
Go to the Website

carles.arus@uab.cat

Back to Portfolio
© 2022 Xartec Salut
Twitter Linkedin-in